-

Öz

Objective: The aim of study is to evaluate the impact of fluorodeoxyglucose positron emission tomography (FDG PET) in the follow-up of medullary thyroid carcionma (MTC) patients who had elevated calcitonin levels after surgery. Materials and Methods: Six patients diagnosed with MTC who referred to our clinic for FDG PET imaging because of the elevated calcitonin levels were included. All were male. Mean age was 52±8 years. Results: In 4 patients whose calcitonin levels were 75 pg/ml, 90pg/ml, 94 pg/ml and 127 pg/ml respectively, there was no evidence for recurrence or metastasis of MTC on FDG PET. FDG PET findings were positive in 2 patients whose calcitonin levels were 1300 pg/ml and 2110 pg/ml respectively. In these patients lymph node metastases and bone metastases were detected. Conclusion: It seems that there is no place to FDG PET for routine imaging of MTC. But here calcitonin levels are important. In patients who have calcitonin levels higher than 1000 pg/ml FDG PET can be very useful and detect a lot of lesion foci. Also allowing to whole body imaging is a significant advantage of it.

Anahtar Kelimeler

• Medullary thyroid carcinoma, FDG PET, Calcitonin.

MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET

Öz

ÖZET
Amaç: Çalışmanın amacı cerrahi sonrası yüksek kalsitonin seviyelerine sahip medüller tiroid karsinomlu (MTK) hastaların takibinde florodeoksiglikoz pozitron emisyon tomografisinin (FDG PET) etkinliğini değerlendirmektedir. Gereç ve Yöntemler: Çalışmaya yüksek kalsitonin seviyeleri nedeniyle kliniğimize FDG PET görüntüleme için yönlendirilen MTK tanılı 6 hasta dahil edildi. Bütün hastalar erkekti. Yaş ortalaması 52±8 idi.
Bulgular: Kalsitonin seviyeleri sırasıyla75 pg/ml, 90pg/ml, 94 pg/ml ve 127 pg/ml olan 4 hastada FDG PET görüntülemede MTK’nın rekürrens ya da metastazını düşündürecek  bulgu izlenmedi. Kalsitonin  seviyeleri 1300 pg/ml ve 2110 pg/ml olan 2 hastada ise FDG PET bulguları pozitifti. Bu hastalarda lenf nodu ve kemik metastazları saptandı.
Tartışma: Öyle görünüyor ki MTK’nın rutin görüntülemesinde FDG PET’e yer yoktur. Ancak burada kalsitonin seviyeleri önem arz etmektedir. Kalsitonin seviyeleri 1000 pg/ml’den yüksek hastalarda FDG PET oldukça faydalı olabilmekte ve birçok lezyon odağını tespit edebilmektedir. Ayrıca tüm vücut görüntülemeye olanak sağlaması da önemli bir avantajıdır.
Anahtar kelimeler: Medüller tiroid karsinomu, FDG PET, Kalsitonin.

ABSTRACT

Objective: The aim of study is to evaluate the impact of fluorodeoxyglucose positron emission tomography (FDG PET) in the follow-up of medullary thyroid carcionma (MTC) patients who had elevated calcitonin levels after surgery.
Materials and Methods: Six patients diagnosed with MTC who referred to our clinic for FDG PET imaging because of the elevated calcitonin levels were included. All were male. Mean age was 52±8 years.
Results: In 4 patients whose calcitonin levels were 75 pg/ml, 90pg/ml, 94 pg/ml and 127 pg/ml respectively, there was no evidence for recurrence or metastasis of MTC on FDG PET. FDG PET findings were positive in 2 patients whose calcitonin levels were 1300 pg/ml and 2110 pg/ml respectively. In these patients lymph node metastases and bone metastases were detected.
Conclusion: It seems that there is no place to FDG PET for routine imaging of MTC. But here calcitonin levels are important. In patients who have calcitonin levels higher than 1000 pg/ml FDG PET can be very useful and detect a lot of lesion foci. Also allowing to whole body imaging is a significant advantage of it.
Key words: Medullary thyroid carcinoma, FDG PET, Calcitonin.

Anahtar Kelimeler

• Medüller tiroid karsinomu, FDG PET, Kalsitonin.

Kaynakça

1. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 2001;91(9):1797–808.
2. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61(3):299–310.
3. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Non parallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53(2):278–85.
4. Quayle FJ, Moley JF. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol. 2005;89(3):122–9.
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S, 1985-1995. Cancer. 1998;83(12):2638–48.
6. Lairmore TC, Wells SA Jr. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol. 1991;7(2):92–9.
7. Bergholm U, Adami HO, Bergström R, Johansson H, Lundell G, Telenius-Berg M, et al. Clinical characteristics in sporadic and familial medullary thyroid carcinoma: a nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer. 1989;63(6):1196–204.
8. Pitt SC, Moley JF. Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol. 2010;37(6):567-79.

9. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139–48.
10. Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M,et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48(4):501–7. 17 18
11. A, Schurrat T, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006;33(11):1273–9.